BioRN Annual Conference 2023 ++ Speakers ++ Call for Abstract ++ Visit of Belgian Delegation ++ Johnson & Johnson Innovation Roadshow 14 June

*|MC:SUBJECT|*

BioRN News May 2023

View this email in your browser

Dear |FNAME| |LNAME|,

Nurturing and extending connections among regional innovation stakeholders is at the core of BioRN's activities. We bridge members regionally and towards other innovative ecosystems worldwide.
One of the tools that we use to achieve this, is the BioRN Annual Conference. Since 2009, each year the conference has been a valuable source of top information, lively discussions and networking opportunities with international experts from different fields of the life sciences. This year the conference will bring together experts in the field of cell and gene therapies and will address promises and challenges of next-generation approaches in the field.
KEYNOTE Anke Schulte, Head of Cell & Gene Therapy Research and Preclinical Development, Bayer
Carsten Müller-Tidow, University Hospital Heidelberg
Ulrike Philippar, Johnson & Johnson
Michael Platten, German Cancer Research Center

Moreover the call for abstracts for the Young Scientists Pitch Competition is open until June 30. We encourage Master- or PhD-Students and Postdocs to send their research abstracts around the conference topic to have the possibility to pitch during the conference in front of an audience from industry and academia experts and compete for a monetary prize.

Boost your visibility by joining the exhibition area. We have still few spots free.
Connect to the delegation from Leuven and Belgium during the conference and in the pre-evening event. Take the chance to listen to interesting talks, have B2B meetings and network.

Johnson & Johnson Innovation in Heidelberg: We are delighted to partner with Johnson & Johnson Innovation (JJI) to bring their Roadshow in Germany to Heidelberg on 14 June. The JJI team with Nerida Scott, Head of Johnson & Johnson Innovation EMEA, Elena Fernandez Kleinlein, Head of JLABS EMEA and Anthony Gemmell, Head JJI EMEA Pharma Early Innovation Partnering Network will present their collaboration model and are looking forward to meet in-person with entrepreneurs, academics, tech transfer offices, and other leaders in lifesciences innovation from our regional ecosystem. Join the event!

Enjoy the news from our network and mark your calendar for the upcoming events!

Annalisa Zuccotti
Events & Communication Lead
BioRN Life Science Cluster Rhine-Neckar

01| Research Highlights & News

Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic [more]

BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus [more]

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases [more]

DKFZ:

Epigenetic profiling identifies potential COPD treatment targets [more]
Reduced cancer mortality with daily vitamin D intake [more]
"G7 Cancer": Seven leading organizations strengthen their coordination to accelerate progress against cancer worldwide [more]
Obesity as a risk factor for colorectal cancer underestimated so far - Weight loss before diagnosis obscures correlations [more]

DKFZ & KiTZ: First company in the world to offer preclinical drug tests for children with cancer [more]

Heidelberg University:

New research building for the engineering of life-inspired molecular systems [more]
Luring the Virus Into a Trap: Heidelberg researchers describe mechanisms that could help prevent infections with the influenza A and Ebola viruses [more]

INNAXE: How can health and lifesciences clusters enhance their support to their ecosystems and enhance their innovation capacities? Guidelines for ecosystem monitoring [more]

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease [more]

Funding opportunities for SMEs from the biomanufacturing and medical technology sectors [more]

02 | New Members

AaviGen is a pre-clinical stage biotechnology company focused on the development of curative gene therapies for genetic and acquired cardiovascular and cardiopulmonary diseases. Its lead program employs heart-specific recombinant Adeno-Associated Viruses (AAV) to bring therapeutic genes with unprecedented safety and precision to the diseased heart via a simple one-time intravenous injection.

The company brings together leading knowledge in clinical cardiology& pneumology, virology&genetic vector engineering as well as gene therapy medicinal product development.

medicalvalues turns medical data points into actionable diagnostic insights. The AI-based solution from medicalvalues supports the complex diagnostic decision-making process and enables integrated diagnostics through the interdisciplinary and cross-sectoral aggregation and contextualization of diagnostic data.
By combining real-time patient information (e.g., symptoms, laboratory results, imaging, clinical pre-conditions) and research knowledge (medically validated diagnostic pathways), the system provides recommendations for suspected diagnoses, potential differential diagnoses, and the best possible next diagnostic step.

Large companies have a separate department for structural biology providing expertise for drug development, analytical methods, enzyme optimization, understanding of special publications and marketing. For startups and SMEs, it is usually not economical to employ structural biologists and bioinformaticians, which represents a clear competitive disadvantage. STBIO can close this gap by supporting small and medium-sized companies in the field of structural biology through, consulting, training, and project coordination.

03 | Events Spotlight

04 | Event Calendar & Discounts

ON Helix - One Nucleus
June 06, 2023 - Cambridge, UK
10 % discount on ticket price >>

QP Release and the EU Clinical Trial Regulation: Lessons learned One Year on
June 06, 2023 - Online >>

Scientist to Scientist by Thermo Fisher Scientific
June 06, 2023 - Heidelberg >>

Optimizing the cell therapy patient journey through integrated CRO/CDMO partnership
June 06, 2023 - Online >>

Benefits of an integrated approach to gene therapy development and manufacturing: Mitigating risks to cost, timelines, and commercialization strategy
June 08, 2023 - Online >>

Clinical Innovation: A Futureproof Trial Strategy
June 13, 2023 - Rotterdam (NL) & Virtual >>

AI and the Future of Surgical Care
June 13, 2023 - Online >>

JOHNSON & JOHNSON INNOVATION ROADSHOW IN GERMANY
June 14, 2023 - Heidelberg >>

Connect in Pharma 2023
June 14-15, 2023 - Palexpo, Geneva >>

BioMedX Lunch Talk Series - Preparing the Battlefield – How Cells Maintain Their Vigilance Against Viral Intruders
June 15, 2023 - Heidelberg >>

EMEA Multiomics Discovery Symposium Series
June 21, 2023 - Heidelberg, Germany >>

11th Antibody Industrial Symposium - AIS2023
June 22-23, 2023 - Tours, France
10 % discount on ticket price >>

TREFFpunkt GESUNDHEITSINDUSTRIE
June 28, 2023 - Stuttgart, Germany >>

Einschnitte – Einblicke: Digitalisierung | Fusion | KI in der Chirurgie
June 28, 2023 - Tübingen, Germany >>

Life Sciences Baltics
September 20-21, 2023 - Vilnius, Lithuania
15 % discount on ticket price >>

Bio-Europe
November 06-08, 2023 - Munich, Germany
900 € discount until 28th July and 10 % discount on later registration for BioRN Members >>

7th Immunotherapies & Innovations for Infectious Diseases Congress 2023 - I4ID2023
November 22-23, 2023 - Lyon, France
10 % discount for BioRN Members >>

NLSDays 2023 - Nordic Life Science Days
November 29-30, 2023 - Copenhagen, Denmark
Booth in the German Pavillon (incl. Ticket for 1,200 €)
15% discount for BioRN Members >>